Table 4.

Cross-disease Comparison of Microarray Profiles of 12 Validated mRNA Biomarkers

Gene symbol	Pancreatic cancer	Oral cancer	Lung cancer	Breast cancer
MBD3L2	0.011	0.391	0.770	0.419
KRAS	< 0.001	0.248	0.346	0.906
STIM2	0.013	0.160	0.479	0.963
DMXL2	0.009	0.869	0.056	0.226
ACRV1	0.004	0.946	0.304	0.397
DMD	0.008	0.633	0.979	0.558
CABLES1	0.002	0.574	0.096	0.473
TK2	0.014	0.966	0.007	0.311
GLTSCR2	0.006	0.417	0.336	0.073
CDKL3	< 0.001	0.107	0.227	0.190
TPT1	0.007	0.213	0.331	0.422
DPM1	0.005	0.135	0.082	0.428

Cancer specificity of the twelve validated mRNA biomarkers were evaluated across different microarray discovery studies that has been performed in our laboratory on diverse cancers, including pancreatic cancer, oral cancer, breast cancer and lung cancer. T-test p-values were calculated for each transcript between cancers and healthy controls in different microarray studies. Except TK2 that also showed significant variation in lung cancer microarray study (P = 0.007), the rest mRNAs/transcripts that showed significant variations in pancreatic cancer study were not significantly altered in other cancer microarray studies (P > 0.05).